Last reviewed · How we verify
NCT01762813: ACROBATICC
Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer
trial testing open and laparoscopic surgery in Colorectal Cancer in 1,200 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Helse Stavanger HF |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,200 |
| Start date | 1 January 2013 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- open and laparoscopic surgery
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Helse Stavanger HF — full company profile →
Who can join
18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
* A prospective, observational study on clinical outcomes of surgical management of primary and metastatic colorectal cancer * Prospective collection of tissues to explore potential biomarkers in blood and/or primary or secondary cancers and/or normal colon
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Watson MM, Lea D, Gudlaugsson E, Skaland I, et al · · 2020 · cited 17× · PMID 32314040 · DOI 10.1007/s00262-020-02573-0 -
Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis.
Søreide K, Watson MM, Lea D, Nordgård O, et al · · 2016 · cited 13× · PMID 27357108 · DOI 10.1186/s12967-016-0951-4 -
A template to quantify the location and density of CD3 + and CD8 + tumor-infiltrating lymphocytes in colon cancer by digital pathology on whole slides for an objective, standardized immune score assessment.
Lea D, Watson M, Skaland I, Hagland HR, et al · · 2021 · cited 12× · PMID 33439293 · DOI 10.1007/s00262-020-02834-y -
Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots.
Watson MM, Lea D, Hagland HR, Søreide K. · · 2019 · cited 9× · PMID 31677491 · DOI 10.1016/j.tranon.2019.08.009 -
Neoadjuvant Immunotherapy Followed by Surgery Compared with Upfront Surgery Alone in Operable Colon Cancer with Deficient Mismatch Repair: Modeling Oncological Outcomes and Numbers Needed to Treat.
Kanani A, Veen T, Lea D, Zaharia C, et al · · 2025 · cited 2× · PMID 39738901 · DOI 10.1245/s10434-024-16755-y -
Pre- and postoperative expression of circulating CEACAM1 and CEACAM6 using a nanoparticle-supported, lectin-specific assay detected in serum from patients with colorectal cancer.
Kanani A, Alexeeva M, Vinod R, Pettersson K, et al · · 2026 · PMID 42017600 · DOI 10.1080/00365521.2026.2661974
Verify or expand the search:
- PubMed search for NCT01762813
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Helse Stavanger HF trials
Trials by the same sponsor.
- NCT06983002 — Bridging Affect Consciousness, Mentalization and Trauma- Exploring an Integrative Treatment Approach for Personality Dis · NA · not yet recruiting
- NCT06774261 — Phenserine on the Alzheimer's Treatment Horizon, Study 1 · Phase 1 · not yet recruiting
- NCT06362707 — Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD) · Phase 2 · recruiting
- NCT06211907 — Small Macular Holes Treated With Air · NA · recruiting
- NCT06150274 — Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01762813 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helse Stavanger HF
- Last refreshed: 24 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01762813.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing